|View printer-friendly version|
The podium presentation and two abstracts include:
- The podium presentation titled, “Restoring Light Perception with Retinal Tissue Grafting Derived from Human Pluripotent Stem Cells” will be presented by Dr.
Igor Nasonkin, BioTime’s head of research, on Monday, August 28th during the Medical Advancements in Operational and Clinical Vision Protection and Treatment session. This presentation outlines the potential use of BioTime’s pluripotent cell technology to help the body restore vision following blast exposure. The preclinical study demonstrates positive results following grafting of these cells into sub-retinal tissue, as well as improvement in tracking vision over an eight month period.
- The abstract titled, “Repair of Trauma-Induced Subcutaneous Contour Defects Using Autologous Adipose Derived Stem Cells Implanted in Renevia® Hydrogel Matrix” will be presented by Dr.
Thomas Zarembenski, BioTime’s head of external R&D, on Tuesday, August 29th during the Head, Neck & Facial Trauma/ Otolaryngology & Plastic Surgery Demo session. This abstract describes safety data following the use of Renevia® in facial contour defects as a result of trauma.
- The abstract titled, “Vision Preservation Following Blast Injury Through Continuous Paracrine Delivery of Trophic Factors to Degenerating Optic Nerve and Retina” will be presented by Dr. Nasonkin, on
Tuesday, August 29th during the Medical Advancements in Operational and Clinical Vision Protection and Treatment session. This abstract outlines two methodologies used to differentiate pluripotent cells, followed by their implantation in mouse models with degenerating optic nerve and retinal tissue. The study demonstrates successful, tumor-free integration with retinal tissue, which is expected to slow, halt or improve vision degeneration over time.
“The MHSRS symposium is hosted by the
To receive ongoing
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
David Nakasone, 510-871-4188
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Doug Sherk, 646-445-4800
JQA Partners, Inc.
Jules Abraham, 917-885-7378